Longer persistence seen with Upadacitinib versus tumor necrosis factor inhibitors in rheumatoid arthritis

Article excerpt

Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.